1
|
Mei Y, Chen Y, Zhang H, Fan W, Liu L, Wang Z, Wang J, Fan L, Xiong A, Yang L, Wang Z. Borneol acts as an adjuvant agent to enhance the oral absorption of Panax notoginseng saponins in rats: Effect of optical configuration and compatibility ratios. JOURNAL OF ETHNOPHARMACOLOGY 2024; 331:118331. [PMID: 38734392 DOI: 10.1016/j.jep.2024.118331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 05/05/2024] [Accepted: 05/09/2024] [Indexed: 05/13/2024]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Panax notoginseng saponins (PNS), as the main active component of Panax notoginseng, shows broad pharmacological effects but with low oral bioavailability. Borneol (BO) is commonly used as an adjuvant drug in the field of traditional Chinese medicine, which has been proven to facilitate the absorption of ginsenosides such as Rg1 and Rb1 in vivo. The presence of chiral carbons has resulted in three optical isomers of BO commercially available in the market, all of which are documented by national standards. AIM OF THE STUDY This study aimed to investigate the role of BO in promoting the oral absorption of PNS from the perspective of optical configuration and compatibility ratios. MATERIALS AND METHODS In this study, an ultra-performance liquid chromatography coupled with triple quadrupole-linear ion trap tandem mass spectrometry (UPLC-QTRAP-MS/MS) method was validated and applied to determine the concentrations of five main saponins in PNS in rat plasma. The kinetic characteristics of PNS were compared when co-administered with BO based on optical isomerism and different compatibility ratios. RESULTS The results showed that BO promoted the exposure of PNS in rats. Three forms of BO, namely d-borneol (DB), l-borneol (LB), and synthetic borneol (SB), exhibited different promotion strengths. SB elevated PNS exposure in rats more than DB or LB. It is also interesting to note that under different compatibility ratios, SB can exert a strong promoting effect only when PNS and BO were combined in a 1:1 ratio (PNS 75 mg/kg; BO 75 mg/kg). As a pharmacokinetic booster, the dosage of BO is worthy of consideration and should follow the traditional medication principles of Chinese medicine. CONCLUSIONS This study shed new light on the compatible use of PNS and BO from the perspective of "configuration-dose-influence" of BO. The results provide important basis for the clinical application and selection of BO.
Collapse
Affiliation(s)
- Yuqi Mei
- The MOE Key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and SATCM Key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
| | - Yan Chen
- The MOE Key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and SATCM Key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
| | - Haoyue Zhang
- The MOE Key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and SATCM Key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
| | - Wenxiang Fan
- The MOE Key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and SATCM Key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
| | - Longchan Liu
- The MOE Key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and SATCM Key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
| | - Ziying Wang
- The MOE Key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and SATCM Key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
| | - Jinyuan Wang
- The MOE Key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and SATCM Key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
| | - Linhong Fan
- The MOE Key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and SATCM Key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
| | - Aizhen Xiong
- The MOE Key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and SATCM Key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Shanghai R & D Center for Standardization of Traditional Chinese Medicines, Shanghai, 201203, China.
| | - Li Yang
- The MOE Key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and SATCM Key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Shanghai R & D Center for Standardization of Traditional Chinese Medicines, Shanghai, 201203, China.
| | - Zhengtao Wang
- The MOE Key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and SATCM Key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Shanghai R & D Center for Standardization of Traditional Chinese Medicines, Shanghai, 201203, China.
| |
Collapse
|
2
|
Long Y, Lei F, Hu J, Zheng Z, Gui S, He N. Design and Evaluation of Ophthalmic Thermosensitive In Situ Gel of Compound Salvia. AAPS PharmSciTech 2024; 25:191. [PMID: 39164556 DOI: 10.1208/s12249-024-02913-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2024] [Accepted: 08/01/2024] [Indexed: 08/22/2024] Open
Abstract
The compound Salvia Recipe has been shown to have a relatively significant curative effect in management of cardiovascular and cerebrovascular diseases. This work aimed to prepare a thermosensitive in situ gel (ISG) delivery system that utilizes Poloxamer 407, Poloxamer 188, and hydroxypropyl methylcellulose for ocular administration of the compound Salvia recipe to treat cardiovascular and cerebrovascular diseases. The central composite design-response surface method was utilized to improve the prescription of the gel. The formulated gel was characterized and assessed in terms of stability, retention time, in vitro release, rheology, ocular irritation, pharmacokinetics studies, and tissue distribution. The gel was a liquid solution at room temperature and became semisolid at physiological temperature, prolonging its stay time in the eye. Pharmacokinetics and tissue distribution experiments indicated that thermosensitive ISG had enhanced targeting of heart and brain tissues. Additionally, it could lower drug toxicity and side effects in the lungs and kidneys. The compound Salvia ophthalmic thermosensitive ISG is a promising drug delivery system for the management of cardiovascular and cerebrovascular illnesses.
Collapse
Affiliation(s)
- Yanqiu Long
- Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, 350 Longzihu Road, Hefei, AnHui, People's Republic of China
| | - Fang Lei
- Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, 350 Longzihu Road, Hefei, AnHui, People's Republic of China
| | - Jie Hu
- Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, 350 Longzihu Road, Hefei, AnHui, People's Republic of China
| | - Zhiyun Zheng
- Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, 350 Longzihu Road, Hefei, AnHui, People's Republic of China
- Institute of Pharmaceutics, Anhui Academy of Chinese Medical Sciences, Hefei, 230012, People's Republic of China
- Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application, Hefei, 230012, China
- Institute of Pharmaceutics, Anhui Academy of Chinese Medical Sciences, Hefei, 230012, China
| | - Shuangying Gui
- Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, 350 Longzihu Road, Hefei, AnHui, People's Republic of China
- Institute of Pharmaceutics, Anhui Academy of Chinese Medical Sciences, Hefei, 230012, People's Republic of China
- Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application, Hefei, 230012, China
- Institute of Pharmaceutics, Anhui Academy of Chinese Medical Sciences, Hefei, 230012, China
| | - Ning He
- Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, 350 Longzihu Road, Hefei, AnHui, People's Republic of China.
- Institute of Pharmaceutics, Anhui Academy of Chinese Medical Sciences, Hefei, 230012, People's Republic of China.
- Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application, Hefei, 230012, China.
- Institute of Pharmaceutics, Anhui Academy of Chinese Medical Sciences, Hefei, 230012, China.
| |
Collapse
|
3
|
Xie Y, Wang C. Herb-drug interactions between Panax notoginseng or its biologically active compounds and therapeutic drugs: A comprehensive pharmacodynamic and pharmacokinetic review. JOURNAL OF ETHNOPHARMACOLOGY 2023; 307:116156. [PMID: 36754189 DOI: 10.1016/j.jep.2023.116156] [Citation(s) in RCA: 18] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/06/2022] [Revised: 12/24/2022] [Accepted: 01/06/2023] [Indexed: 06/18/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Herbs, along with the use of herb-drug interactions (HDIs) to combat diseases, are increasing in popularity worldwide. HDIs have two effects: favorable interactions that tend to improve therapeutic outcomes and/or minimize the toxic effects of drugs, and unfavorable interactions aggravating the condition of patients. Panax notoginseng (Burk.) F.H. Chen is a medicinal plant that has long been commonly used in traditional Chinese medicine to reduce swelling, relieve pain, clear blood stasis, and stop bleeding. Numerous studies have demonstrated the existence of intricate pharmacodynamic (PD) and pharmacokinetic (PK) interactions between P. notoginseng and conventional drugs. However, these HDIs have not been systematically summarized. AIM OF THE REVIEW To collect the available literature on the combined applications of P. notoginseng and drugs published from 2005 to 2022 and summarize the molecular mechanisms of interactions to circumvent the potential risks of combination therapy. MATERIALS AND METHODS This work was conducted by searching PubMed, Scopus, Web of Science, and CNKI databases. The search terms included "notoginseng", "Sanqi", "drug interaction," "synergy/synergistic", "combination/combine", "enzyme", "CYP", and "transporter". RESULTS P. notoginseng and its bioactive ingredients interact synergistically with numerous drugs, including anticancer, antiplatelet, and antimicrobial agents, to surmount drug resistance and side effects. This review elaborates on the molecular mechanisms of the PD processed involved. P. notoginseng shapes the PK processes of the absorption, distribution, metabolism, and excretion of other drugs by regulating metabolic enzymes and transporters, mainly cytochrome P450 enzymes and P-glycoprotein. This effect is a red flag for drugs with a narrow therapeutic window. Notably, amphipathic saponins in P. notoginseng act as auxiliary materials in drug delivery systems to enhance drug solubility and absorption and represent a new entry point for studying interactions. CONCLUSION This article provides a comprehensive overview of HDIs by analyzing the results of the in vivo and in vitro studies on P. notoginseng and its bioactive components. The knowledge presented here offers a scientific guideline for investigating the clinical importance of combination therapies. Physicians and patients need information on possible interactions between P. notoginseng and other drugs, and this review can help them make scientific predictions regarding the consequences of combination treatments.
Collapse
Affiliation(s)
- Yujuan Xie
- Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, The MOE Key Laboratory for Standardization of Chinese Medicines, Shanghai R&D Centre for Standardization of Chinese Medicines, 1200 Cailun Road, Shanghai, 201203, China
| | - Changhong Wang
- Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, The MOE Key Laboratory for Standardization of Chinese Medicines, Shanghai R&D Centre for Standardization of Chinese Medicines, 1200 Cailun Road, Shanghai, 201203, China.
| |
Collapse
|
4
|
Huang J, Gong MJ, Bai JQ, Su H, Gong L, Huang ZH, Qiu XH, Xu W, Zhang J. Differential Metabolic Profiles of Ginsenosides in Artificial Gastric Juice Using ultra-high-pressure Liquid Chromatography Coupled with Linear ion trap-Orbitrap Mass Spectrometry. Biomed Chromatogr 2022; 36:e5493. [PMID: 36044184 DOI: 10.1002/bmc.5493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Revised: 08/24/2022] [Accepted: 08/26/2022] [Indexed: 11/09/2022]
Abstract
Ginsenosides have poor bioavailability of oral administration and undergo rapid biologic transformation in the complex gastrointestinal environment. Most studies on the metabolism of ginsenosides has focused on gut bacteria, yet gastric juice remains as a non-negligible factor. Metabolic profiles of ginsenoside monomers formed in artificial gastric juice were separately investigated and qualitatively identified by UHPLC-LTQ-Orbitrap MSn . A common pattern of their metabolic pathways was established, showing that ginsenosides were transformed via deglycosylation, hydration and dehydration pathways. Two major structure types, PPTs and PPDs, basically shared similar transformation pathways and yielded deglycosylated, hydrated and dehydrated products. Fragmentation patterns of major ginsenosides were also discussed. Consequently, gastric juice, as the primary link in ginsenoside metabolism and as important as the intestinal flora, produces considerable amount of degraded ginsenosides, providing a partial explanation for the low bioavailabilities of primary ginsenosides.
Collapse
Affiliation(s)
- Juan Huang
- Key Laboratory of Quality Evaluation of Chinese Medicine of the Guangdong Provincial Medical Products Administration, the Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Ming Jiong Gong
- Key Laboratory of Quality Evaluation of Chinese Medicine of the Guangdong Provincial Medical Products Administration, the Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Jun Qi Bai
- Key Laboratory of Quality Evaluation of Chinese Medicine of the Guangdong Provincial Medical Products Administration, the Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China
| | - He Su
- Key Laboratory of Quality Evaluation of Chinese Medicine of the Guangdong Provincial Medical Products Administration, the Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Lu Gong
- Key Laboratory of Quality Evaluation of Chinese Medicine of the Guangdong Provincial Medical Products Administration, the Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Zhi Hai Huang
- Key Laboratory of Quality Evaluation of Chinese Medicine of the Guangdong Provincial Medical Products Administration, the Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.,Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangdong provincial Hospital of Chinese Medicine, Guangzhou, China
| | - Xiao Hui Qiu
- Key Laboratory of Quality Evaluation of Chinese Medicine of the Guangdong Provincial Medical Products Administration, the Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.,Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangdong provincial Hospital of Chinese Medicine, Guangzhou, China
| | - Wen Xu
- Key Laboratory of Quality Evaluation of Chinese Medicine of the Guangdong Provincial Medical Products Administration, the Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.,Dept Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
| | - Jing Zhang
- Key Laboratory of Quality Evaluation of Chinese Medicine of the Guangdong Provincial Medical Products Administration, the Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China
| |
Collapse
|
5
|
Zheng D, Chu Y, Li S, Zhou S, Li W, Xie Y, Sun H. Enhancing effect of borneol on pharmacokinetics of ginsenoside Rb 1 , ginsenoside Rg 1 and notoginsenoside R 1 in healthy volunteers after oral administration of compound Danshen dropping pills (CDDP). Biomed Chromatogr 2022; 36:e5311. [PMID: 34981536 DOI: 10.1002/bmc.5311] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Revised: 12/08/2021] [Accepted: 12/13/2021] [Indexed: 11/10/2022]
Abstract
Borneol (Bingpian), a monoterpenoid pharmaceutical ingredient, is commonly used as a main composition in traditional Chinese medicine (TCM) preparations such as compound Danshen dropping pills (CDDP), and has also been approved by the US FDA as a flavoring substance or adjuvant in food. Borneol plays a regulating and guiding role as messenger drug in CDDP. However, the effect of borneol on the pharmacokinetics of the components of CDDP in human plasma is unclear. In this study, we investigate the effects of borneol on the pharmacokinetics of ginsenoside Rb1 (Rb1 ), ginsenoside Rg1 (Rg1 ) and notoginsenoside R1 (NR1 ) in CDDP. We used a double-cycle crossover-administration model in twelve healthy male volunteers, giving CDDP with borneol (drug T) and without borneol (drug R). The selective response monitoring (SRM) mode was used for mass spectrometry quantification in the positive mode. As a result, we found that borneol could significantly affect the pharmacokinetic parameters of notoginsenosides, and increase the absorption and systemic exposure of Rb1 , Rg1 and NR1 in human plasma by about 1.85 to 3.71 times.
Collapse
Affiliation(s)
- Dayong Zheng
- School of Pharmacy, North China University of Science and Technology, Tangshan, China
| | - Yang Chu
- State Key Laboratory of Core Technology in Innovation Chinese Medicine, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.,Tasly Academy, Tasly Holding Group Co., Ltd., Tianjin, China
| | - Shuming Li
- State Key Laboratory of Core Technology in Innovation Chinese Medicine, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.,Tasly Academy, Tasly Holding Group Co., Ltd., Tianjin, China
| | - Shuiping Zhou
- State Key Laboratory of Core Technology in Innovation Chinese Medicine, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.,Tasly Academy, Tasly Holding Group Co., Ltd., Tianjin, China
| | - Wei Li
- School of Pharmacy, North China University of Science and Technology, Tangshan, China
| | - Yuesheng Xie
- School of Pharmacy, North China University of Science and Technology, Tangshan, China
| | - He Sun
- State Key Laboratory of Core Technology in Innovation Chinese Medicine, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.,Tasly Academy, Tasly Holding Group Co., Ltd., Tianjin, China
| |
Collapse
|
6
|
Li J, Xie Q, Ma R, Li Y, Yuan J, Ren M, Li H, Wang J, Lu D, Xu Z, Wang J. Recent Progress on the Synergistic Antitumor Effect of a Borneol-Modified Nanocarrier Drug Delivery System. Front Med (Lausanne) 2021; 8:750170. [PMID: 34901063 PMCID: PMC8655685 DOI: 10.3389/fmed.2021.750170] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Accepted: 10/11/2021] [Indexed: 01/02/2023] Open
Abstract
Borneol, a traditional Chinese medicine, can enhance therapeutic efficacy by guiding the active ingredients to the target site. Reportedly, borneol improves the penetration capacity of the nasal, cornea, transdermal, intestinal, and blood-brain barriers. Although nanotechnology dramatically changed the face of oncology by targeting tumor sites, the efficiency of nanoparticles delivered to tumor sites is very low, with only 0.7% of the total particles delivered. Thus, based on the penetration ability and the inhibition drug efflux of borneol, it was expected to increase the targeting and detention efficacy of drugs into tumor sites in nanocarriers with borneol modification. Borneol modified nanocarriers used to improve drug-targeting has become a research focus in recent years, but few studies in this area, especially in the antitumor application. Hence, this review summarizes the recent development of nanocarriers with borneol modification. We focus on the updated works of improving therapeutic efficacy, reducing toxicity, inhibiting tumor metastasis, reversing multidrug resistance, and enhancing brain targeting to expand their application and provide a reference for further exploration of targeting drug delivery systems for solid tumor treatment.
Collapse
Affiliation(s)
- Jinxiu Li
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Qian Xie
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Rong Ma
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Yong Li
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Jianmei Yuan
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Mihong Ren
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Hongyan Li
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Jiajun Wang
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Danni Lu
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Zhuo Xu
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Jian Wang
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| |
Collapse
|
7
|
Liu H, Yang J, Yang W, Hu S, Wu Y, Zhao B, Hu H, Du S. Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases. DRUG DESIGN DEVELOPMENT AND THERAPY 2020; 14:551-565. [PMID: 32103897 PMCID: PMC7012233 DOI: 10.2147/dddt.s240511] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/29/2019] [Accepted: 01/28/2020] [Indexed: 12/13/2022]
Abstract
Notoginsenoside (NG)-R1 is one of the main bioactive compounds from Panax notoginseng (PN) root, which is well known in the prescription for mediating the micro-circulatory hemostasis in human. In this article, we mainly discuss NG-R1 in metabolism and the biological activities, including cardiovascular protection, neuro-protection, anti-diabetes, liver protection, gastrointestinal protection, lung protection, bone metabolism regulation, renal protection, and anti-cancer. The metabolites produced by deglycosylation of NG-R1 exhibit higher permeability and bioavailability. It has been extensively verified that NG-R1 may ameliorate ischemia-reperfusion (IR)-induced injury in cardiovascular and neuronal systems mainly by upregulating the activity of estrogen receptor α-dependent phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) and nuclear factor erythroid-2-related factor 2 (NRF2) pathways and downregulating nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. However, no specific targets for NG-R1 have been identified. Expectedly, NG-R1 has been used as a main bioactive compound in many Traditional Chinese Medicines clinically, such as Xuesaitong, Naodesheng, XueShuanTong, ShenMai, and QSYQ. These suggest that NG-R1 exhibits a significant potency in drug development.
Collapse
Affiliation(s)
- Hai Liu
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China.,College of Pharmacy, Gannan Medical University, Ganzhou, Jiangxi, People's Republic of China
| | - Jianqiong Yang
- Department of Clinical Research Center, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, People's Republic of China
| | - Wanqing Yang
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China
| | - Shaonan Hu
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China
| | - Yali Wu
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China
| | - Bo Zhao
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China
| | - Haiyan Hu
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China
| | - Shouying Du
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China
| |
Collapse
|
8
|
Chen XN, Li DQ, Zhao MD, Yu GY, Du SY, Lu Y, Bai J, Li PY, Wu YL, Tian ZH, Zeng YY. Pharmacokinetics of Panax notoginseng Saponins in Adhesive and Normal Preparation of Fufang Danshen. Eur J Drug Metab Pharmacokinet 2018; 43:215-225. [PMID: 28916980 DOI: 10.1007/s13318-017-0433-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
BACKGROUND AND OBJECTIVE Fufang Danshen formula, a famous Chinese patent medicine containing Salvia miltiorrhiza, Panax notoginseng and borneol, has been widely used in the treatment of coronary heart disease. The application is restricted by low bioavailability partly due to Panax notoginseng saponins (PNS) instability and low in vivo absorption. Thus, adhesive pellets were developed to improve bioavailability. The objectives of the present study were to evaluate the adhesive preparation by describing PNS's plasma pharmacokinetics in vivo and compare adhesive micro pills with normal preparation. METHOD LC-MS/MS method was established to analyze five ingredients, notoginsenoside R1 (R1), ginsenoside Rg1 (Rg1), ginsenoside Rb1 (Rb1), ginsenoside Re (Re), and ginsenoside Rd (Rd), in rats' plasma to describe the pharmacokinetic parameters of PNS. RESULTS The pharmacokinetic parameters were significantly different after oral administration three formulations. The results show adhesive formulations are superior to Fufang Danshen tablet (FDT); there are differences between the two adhesive, but not obvious. CONCLUSIONS It was found that the modification with adhesive materials improved PNS bioavailability in Fufang Danshen formula. These findings provide a way for further in vivo evaluation of different formulations.
Collapse
Affiliation(s)
- Xiao-Nan Chen
- New Technology and New Dosage Forms of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100102, China
| | - Dan-Qi Li
- New Technology and New Dosage Forms of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100102, China
| | - Meng-di Zhao
- New Technology and New Dosage Forms of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100102, China
| | - Gang-Yan Yu
- New Technology and New Dosage Forms of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100102, China
| | - Shou-Ying Du
- New Technology and New Dosage Forms of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100102, China.
| | - Yang Lu
- New Technology and New Dosage Forms of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100102, China.
| | - Jie Bai
- New Technology and New Dosage Forms of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100102, China
| | - Peng-Yue Li
- New Technology and New Dosage Forms of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100102, China
| | - Ya-Li Wu
- New Technology and New Dosage Forms of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100102, China
| | - Zhi-Hao Tian
- New Technology and New Dosage Forms of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100102, China
| | - Yan-Ying Zeng
- New Technology and New Dosage Forms of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100102, China
| |
Collapse
|
9
|
Zhang X, Ma R, Liu X, Jiang X, Wang L. Simultaneous determination of ginsenoside Rg1, Re and notoginsenoside R1in human plasma by LC-MS/MS and its application in a pharmacokinetic study in Chinese volunteers. Biomed Chromatogr 2016; 30:1915-1921. [PMID: 27219100 DOI: 10.1002/bmc.3766] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2016] [Revised: 05/09/2016] [Accepted: 05/18/2016] [Indexed: 11/10/2022]
Affiliation(s)
- Xiqian Zhang
- Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy; Sichuan University; Chengdu 610041 Sichuan China
| | - Rujun Ma
- Chengdu Huasun Group Inc. Ltd; Chengdu 610075 Sichuan China
| | - Xiaojuan Liu
- Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy; Sichuan University; Chengdu 610041 Sichuan China
| | - Xuehua Jiang
- Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy; Sichuan University; Chengdu 610041 Sichuan China
| | - Ling Wang
- Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy; Sichuan University; Chengdu 610041 Sichuan China
| |
Collapse
|
10
|
Synergism of Chinese Herbal Medicine: Illustrated by Danshen Compound. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2016; 2016:7279361. [PMID: 27190537 PMCID: PMC4846759 DOI: 10.1155/2016/7279361] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/19/2015] [Revised: 01/05/2016] [Accepted: 02/16/2016] [Indexed: 02/06/2023]
Abstract
The primary therapeutic effects of Chinese herbal medicine (CHM) are based on the properties of each herb and the strategic combination of herbs in formulae. The herbal formulae are constructed according to Chinese medicine theory: the “Traditional Principles for Constructing Chinese Herbal Medicinal Formulae” and the “Principles of Combining Medicinal Substances.” These principles of formulation detail how and why multiple medicinal herbs with different properties are combined together into a single formula. However, the concept of herbal synergism in CHM still remains a mystery due to lack of scientific data and modern assessment methods. The Compound Danshen Formula (CDF) is a validated formula that has been used to treat a variety of diseases for hundreds of years in China and other countries. The CDF will be employed to illustrate the theory and principle of Chinese herbal medicine formulation. The aim of this review is to describe how Chinese herbal medicinal formulae are constructed according to Chinese medicine theory and to illustrate with scientific evidence how Chinese herbs work synergistically within a formula, thereby supporting Chinese medicine theory and practice.
Collapse
|
11
|
Long W, Zhang SC, Wen L, Mu L, Yang F, Chen G. In vivo distribution and pharmacokinetics of multiple active components from Danshen and Sanqi and their combination via inner ear administration. JOURNAL OF ETHNOPHARMACOLOGY 2014; 156:199-208. [PMID: 25218322 DOI: 10.1016/j.jep.2014.08.041] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2014] [Revised: 08/27/2014] [Accepted: 08/30/2014] [Indexed: 06/03/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Salvia miltiorrhiza Bunge (Labiatae sp. plant, Chinese name Danshen) and Panax notoginseng (Burk.) F. H. Chen (Araliaceae plant, Chinese name Sanqi) have a long history in treating coronary heart disease, cerebrovascular disease and inner ear disorders in traditional Chinese medicine. To provide a rational basis for the use of these herbs in clinical practice, we investigated the in vivo distribution and pharmacokinetics of marker agents in Danshen and Sanqi via intravenous and inner ear administration and explored the potential interactions of these agents in compound prescription. MATERIALS AND METHODS Guinea pigs were given Danshen extracts (salvianolic acid B, tanshinone IIA), Sanqi extracts (Panax notoginseng saponins) and combination of the two extracts via intravenous and intratympanic administration (IT). Samples from the brain, inner ear perilymph (PL), cerebrospinal fluid (CSF) and plasma were collected at different time points. The concentration of salvianolic acid B (Sal B), tanshinone IIA (Ts IIA), notoginsenoside R₁ (R₁), ginsenoside Rg₁ (Rg₁) and ginsenoside Rb₁ (Rb₁) was determined by high-performance liquid chromatography coupled with a diode array detector (DAD). Pharmacokinetic parameters were estimated using non-compartmental methods. RESULTS Local drug application via inner ear greatly improved drug distribution within the PL, CSF and brain tissues compared with intravenous administration (IV). The values of Cmax and AUC(0-t) after IT were significantly higher than IV. In comparison with IT of Danshen and Sanqi alone, the pharmacokinetic parameters for R₁, Rg₁, Rb₁, Sal B and Ts IIA were markedly different in the compound prescription. The compound compatibility enhanced the transport of Danshen components into the brain through the inner ear and apparently prolonged the retention time in CSF while decreasing the distribution of Sanqi components in the inner ear and brain. CONCLUSIONS The results indicated that local drug application to the inner ear was a more effective delivery route than systemic administration. Co-administration of Danshen and Sanqi could cause significant pharmacokinetic herb-herb interactions in guinea pigs. The multiple active components via inner ear administration might be promising candidates for the treatment of inner ear and brain diseases.
Collapse
Affiliation(s)
- Wei Long
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Shi-chang Zhang
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Lu Wen
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
| | - Lei Mu
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Fan Yang
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Gang Chen
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China; Department of Clinical Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
| |
Collapse
|
12
|
Zhang Y, Ma G, Xie J. Tissue Distribution of Jujuboside A in Sprague-Dawley Rats Determined by an Efficient HPLC–ESI-MS/MS Method. J LIQ CHROMATOGR R T 2014. [DOI: 10.1080/10826076.2014.896821] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Yanqing Zhang
- a College of Biotechnology and Food Science , Tianjin University of Commerce , Tianjin , China
- b Tianjin Key Laboratory of Food Biotechnology , Tianjin , China
| | - Guijie Ma
- a College of Biotechnology and Food Science , Tianjin University of Commerce , Tianjin , China
| | - Junbo Xie
- a College of Biotechnology and Food Science , Tianjin University of Commerce , Tianjin , China
- b Tianjin Key Laboratory of Food Biotechnology , Tianjin , China
| |
Collapse
|
13
|
Liu X, Wu WY, Jiang BH, Yang M, Guo DA. Pharmacological tools for the development of traditional Chinese medicine. Trends Pharmacol Sci 2013; 34:620-8. [PMID: 24139610 DOI: 10.1016/j.tips.2013.09.004] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2013] [Revised: 08/25/2013] [Accepted: 09/16/2013] [Indexed: 02/08/2023]
Abstract
Pharmacology as a modern science was introduced in China approximately 150 years ago, and has been used since then to study traditional Chinese medicine (TCM). Pharmacology has experienced its own development over this time and continues to provide new tools for the study of TCM. In the present review, three models for the pharmacological study of TCM are considered: (i) chemistry-focused study; (ii) target-directed study; and (iii) systems-biology-based study. These approaches correspond to recent developments in pharmacology, and in particular to new tools available to the field. Representative achievements and the pharmacological tools used to study TCM are reviewed. Pharmacology has played, and will continue to play, an indispensable role in elucidating the chemical basis, biological targets, and mechanisms of action of TCM medicines, and in developing a scientific basis for the theory of TCM.
Collapse
Affiliation(s)
- Xuan Liu
- Shanghai Research Center for TCM Modernization, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P.R. China
| | | | | | | | | |
Collapse
|